These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20571610)

  • 21. Application drying time for oxybutynin chloride topical gel.
    Newman DK; Olsen SM; Dahl NV
    Urol Nurs; 2012; 32(5):265-9. PubMed ID: 23472531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
    Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
    J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.
    Kay GG; Staskin DR; MacDiarmid S; McIlwain M; Dahl NV
    Clin Drug Investig; 2012 Oct; 32(10):707-14. PubMed ID: 22909146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intravesical oxybutynin treatment for neurogenic detrusor overactivity : Efficacy and safety data from clinical practice with the first intravesical oxybutynin treatment authorized in Germany].
    Schindler O; Ho H; Leidl Q; Angermund A; Elishar R; Frech-Dörfler M; Hirsch A; Kalke YB; Kirschner-Herrmanns R; Tornic J; Queissert F; Rahnama'i S; Rehme C; Reitz A; Schmitz F; Schultz-Lampel D; Gedamke M
    Urologie; 2024 Jul; 63(7):693-701. PubMed ID: 38755461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal oxybutynin: a review.
    Shaw GL; Patel HR
    Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):435-9. PubMed ID: 17539749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxybutynin and the overactive bladder.
    Andersson KE; Chapple CR
    World J Urol; 2001 Nov; 19(5):319-23. PubMed ID: 11760780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
    MacDiarmid SA
    BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.